- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Mylan's insulin glargine, Lantus®
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 39
- States / cities
- Fresno, California • Greenbrae, California • La Jolla, California + 36 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 72
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes
- Interventions
- Insulin Glargine, Metformin, Prandial insulin, Exenatide
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 12
- States / cities
- San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Chula Vista, California
- Conditions
- Diabetes Mellitus, Type 1 Diabetes
- Interventions
- Rapid-Acting Insulin, Long acting insulin
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 7 Years to 15 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin lispro, Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Concord, California • Fresno, California + 30 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Concord, California • Escondido, California + 46 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy
- Drug · Behavioral
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Insulin Glargine, Insulin Aspart, Insulin Lispro
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Hyperglycemia, Diabetes Mellitus
- Interventions
- Glargine insulin, Lispro insulin, NPH Insulin
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
- Interventions
- Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 730 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 24
- States / cities
- Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- premeal insulin lispro mixtures, insulin glargine, metformin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 11
- States / cities
- Jonesboro, Arkansas • Huntington Park, California • Miami, Florida + 8 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 44
- States / cities
- Mobile, Alabama • Concord, California • Escondido, California + 40 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Glargine, LY2605541, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 47
- States / cities
- Concord, California • Fresno, California • La Mesa, California + 44 more
- Conditions
- Gestational Diabetes, Pregnancy Related
- Interventions
- Insulin
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 430 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Rochester, New York • Philadelphia, Pennsylvania
- Conditions
- Type 1 Diabetes, Type 2 Diabetes
- Interventions
- IIM System, Insulin Lispro and/or Insulin Glargine
- Device · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 5
- States / cities
- Little Rock, Arkansas • Walnut Creek, California • Austin, Texas + 2 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Insulin Glargine, LY2189265, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 884 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 36
- States / cities
- Concord, California • La Mesa, California • Lancaster, California + 33 more
- Conditions
- Diabetes Mellitus
- Interventions
- Lantus (insulin glargine [rDNA origin] injection), Humulin N, Humulin L, Lispro
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 9 Years to 17 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Type 2 Diabetes
- Interventions
- Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
- Conditions
- Hyperglycemia
- Interventions
- Human regular insulin, Insulin lispro, Insulin glargine
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 9 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- SAR342434, Humalog, insulin glargine HOE901
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 51
- States / cities
- Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia